Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Suárez, Juan ^a,c   Romero Zerbo, Yanina ^a   Márquez, Lucia ^b   Rivera, Patricia ^a   Iglesias, Mar ^b   Bermúdez Silva, Francisco J ^a,c   Andreu, Montserrat ^b   Rodríguez de Fonseca, Fernando ^a,c  

^a Hospital University Carlos Haya de Málaga   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; AZATHIOPRINE; CYCLOSPORIN; FATTY ACID AMIDASE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; LIGAND; MESALAZINE; N ACYLETHANOLAMIDE HYDROLIZING ACID AMIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED STUDY; ENZYME DEGRADATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INTESTINE MUSCLE; LAMINA PROPRIA; MALE; MYENTERIC PLEXUS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AMIDOHYDROLASES; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; COLON; ETHANOLAMINES; FEMALE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; INTESTINAL MUCOSA; MALE; MESALAMINE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHOLIPASE D; PPAR ALPHA; PPAR GAMMA; YOUNG ADULT;

ANIMALIA;

EID: 84861477922     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037729     Document Type: Article

References (63)

1. Strober W, Fuss I, Mannon P, (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117: 514-521.
2. Sartor RB, (1997) Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 92 (suppl): 5S-11S.
3. Fiocchi C, (1998) Inflammatory bowel disease: aetiology and pathogenesis. Gastroenterology 115: 182-205.
4. Travis SPL, Jewel DP, (1994) Salicylates for ulcerative colitis-their mode of action. Pharmacol Ther 63: 135-161.
5. Bratts R, Linden M, (1996) Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 10: 81-90.
6. Kho YH, Pool MO, Jansman FG, Harting JW, (2001) Pharmacotherapeutic options in inflammatory bowel disease: an update. Pharm World Sci 23: 17-21.
7. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK, (1998) The peroxisome proliferator-activated receptor g is a negative regulator of macrophage activation. Nature 391: 79-82.
8. Delerive P, Fruchart JC, Staels B, (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169: 453-459.
9. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, et al. (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201: 1205-15.
10. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, et al. (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55: 1341-9.
11. Linard C, Grémy O, Benderitter M, (2008) Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther 324: 911-20.
12. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W, (1996) Differential expression of peroxisome proliferatoractivated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 137: 354-66.
13. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, (1996) Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 222: 844-851.
14. Huin C, Corriveau L, Bianchi A, Keller JM, Collet P, et al. (2000) Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. J Histochem Cytochem 48: 603-611.
15. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, et al. (2003) Impaired expression of peroxisome proliferator-activated receptor g in ulcerative colitis. Gastroenterology 124: 1265-1276.
16. Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, et al. (2003) A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 124: 1315-1324.
17. Dworzanski T, Celinski K, Korolczuk A, Slomka M, Radej S, et al. (2010) Influence of the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, rosiglitazone and antagonist, biphenol-A-diglicydyl ether (BADGE) on the course of inflammation in the experimental model of colitis in rats. J Physiol Pharmacol 61: 683-93.
18. Celinski K, Dworzanski T, Korolczuk A, Piasecki R, Slomka M, et al. (2011) Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats. J Physiol Pharmacol 62: 347-56.
19. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muià C, et al. (2004) Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Lab Invest 84: 1643-54.
20. Mazzon E, Cuzzocrea S, (2007) Absence of functional peroxisome proliferator-activated receptor-alpha enhanced ileum permeability during experimental colitis. Shock 28: 192-201.
21. Esposito E, Mazzon E, Paterniti I, Dal Toso R, Pressi G, et al. (2010) PPAR-alpha contributes to the anti-inflammatory activity of verbascoside in a model of inflammatory bowel disease in mice. PPAR Res 2010: 917312.
22. Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, et al. (2008) Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids. Mol Pharmacol 73: 323-37.
23. Riccardi L, Mazzon E, Bruscoli S, Esposito E, Crisafulli C, et al. (2009) Peroxisome proliferator-activated receptor-alpha modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice. Shock 31: 308-16.
24. Tsuboi K, Takezaki N, Ueda N, (2007) The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 4: 1914-25.
25. Tsuboi K, Zhao LY, Okamoto Y, Araki N, Ueno M, et al. (2007) Predominant expression of lysosomal N-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies. Biochim Biophys Acta 1771: 623-32.
26. Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, et al. (2009) Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A 106: 20966-20971.
27. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, et al. (2004) The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209.
28. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, et al. (2006) Upregulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20: 568-570.
29. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yuce B, et al. (2008) Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med 86: 925-936.
30. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, et al. (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 (Suppl A): 5-36.
31. Lennard-Jones JE, Shivananda S, (1997) Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 9: 353-9.
32. Truelove SC, Witts LJ, (1955) Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2: 1041-8.
33. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, et al. (2007) A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132: 763-86.
34. Suárez J, Bermúdez-Silva FJ, Mackie K, Ledent C, Zimmer A, et al. (2008) Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol 509: 400-21.
35. Marquéz L, Suárez J, Iglesias M, Bermudez-Silva FJ, Rodríguez de Fonseca F, et al. (2009) Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS ONE 4: e6893.
36. Cross RK, Wilson KT, (2003) Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 9: 179-89.
37. Sklyarov AY, Panasyuk NB, Fomenko IS, (2011) Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis. J Physiol Pharmacol 62: 65-73.
38. Paukkeri EL, Leppänen T, Sareila O, Vuolteenaho K, Kankaanranta H, et al. (2007) PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. Br J Pharmacol 152: 1081-91.
39. Brown WA, Farmer KC, Skinner SA, Malcontenti-Wilson C, Misajon A, et al. (2000) 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 45: 1578-84.
40. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W, (2003) Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24: 443-51.
41. Clapper ML, Gary MA, Coudry RA, Litwin S, Chang WC, et al. (2008) 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 14: 1341-7.
42. Tromm A, Griga T, May B, (1999) Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties. Hepatogastroenterology 46: 3124-35.
43. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, et al. (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer: a basis for new therapeutic strategies. J Exp Med 193: 827-838.
44. Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, et al. (2002) Peroxisome proliferatoractivated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 8: 330-339.
45. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N, (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279: 5298-305.
46. Ueda N, Tsuboi K, Uyama T, (2010) Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801: 1274-85.
47. Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ, (2002) The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 9: 663-674.
48. Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, et al. (2001) An anorexic lipid mediator regulated by feeding. Nature 414: 209-212.
49. Nielsen MJ, Petersen G, Astrup A, Hansen HS, (2004) Food intake is inhibited by oral oleoylethanolamide. J Lipid Res 45: 1027-1029.
50. Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, et al. (2007) Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 282: 1518-28.
51. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425: 90-93.
52. Lo Verme J, La Rana G, Russo R, Calignano A, Piomelli D, (2005) The search for the palmitoylethanolamide receptor. Life Sci 77: 1685-1698.
53. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, et al. (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
54. McKinney MK, Cravatt BF, (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74: 411-432.
55. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, et al. (2005) Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 280: 11082-11092.
56. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF, (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals, J Biol Chem 281: 36569-36578.
57. Ueda N, Tsuboi K, Uyama T, (2010) N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res 49: 299-315.
58. Ueda N, Puffenbarger RA, Yamamoto S, Deutsch DG, (2000) The fatty acid amide hydrolase (FAAH). Chem Phys Lipids 108: 107-21.
59. Nugent SG, Kumar D, Rampton DS, Evans DF, (2001) Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48: 571-7.
60. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, et al. (2008) Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 10: R43.
61. Battista N, Bari M, Tarditi A, Mariotti C, Bachoud-Lévi AC, et al. (2007) Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol Dis 27: 108-16.
62. Zhu C, Solorzano C, Sahar S, Realini N, Fung E, et al. (2011) Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol 79: 786-92.
63. Malcher-Lopes R, Franco A, Tasker JG, (2008) Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. Eur J Pharmacol 583: 322-39.